Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 3Phase 4 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Lymphoma, Non-Hodgkin 5Leukemia, Lymphocytic, Chronic, B-Cell 4Neoplasms 2Lymphoma, B-Cell, Marginal Zone 2Arthritis, Rheumatoid 2Waldenstrom Macroglobulinemia 1Sjogren's Syndrome 1Neoplasm, Residual 1Mediastinal Neoplasms 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Lymphohistiocytosis, Hemophagocytic 1Lymphatic Diseases 1Leukemia, B-Cell 1Leukemia 1Heart Failure 1Epstein-Barr Virus Infections 1Burkitt Lymphoma 1

Interventions

ofatumumab 1obinutuzumab 1ibrutinib 1acalabrutinib 1Rituximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Leukemia, B-Cell × Rituximab × Clear all
NCT06651970 2026-05-18

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

AstraZeneca

Phase 4 Recruiting
60 enrolled
LymphoidOther hematologic neoplasm

Heart Failure, Lymphatic Diseases, Leukemia, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡